pharma

Scientists incorporate genetic analyses to streamline and accelerate clinical trials

Scientists analyze a therapeutic protein’s secondary structure to confirm drug efficacy and safety.

Reliable protein stability and similarity measurements using microfluidic modulation spectroscopy

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Advice for new principal investigators starting their first research laboratories!

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

The government is assisting Johnson & Johnson and Moderna with expediting clinical testing while at the same time prepping for large-scale manufacturing.

The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.

Originally intended for basic neuroscience research, the drugs were ultimately hijacked for illicit recreational use.

Analyses of blood from thousands of people show distinct protein profiles are linked to complex diseases of aging.

As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.

In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.

The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.

Researchers use several different strategies to deliver a one-two punch.

The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.

The drug may worsen future infections for people who haven't already been exposed to the virus.